12 Stocks That Could Split in the Near Future

2. Eli Lilly And Co. (NYSE:LLY)

Share Price as of January 19: $725.72

Surge in Share Price in 5 Years: 419.93%

Stock Split Confirmed: No

Number of Hedge Fund Holders: 106

Eli Lilly And Co. (NYSE:LLY) is a pharmaceutical company that discovers, develops, and markets human medications. The company’s growth is mainly driven by the increasing demand for weight loss and diabetes treatments. It has a strong pipeline of glucagon-like peptide-1 (GLP-1) receptor agonist drugs. This means that it helps manage diabetes and weight by affecting certain hormones in the body.

In FQ4 2024, the company’s weight-loss drug sales fell short, with Mounjaro revenue at $3.5 billion (vs. the $5.35 billion estimate) and Zepbound at $1.9 billion (vs. the $2.08 billion estimate). This was due to slower-than-expected US demand and low inventories. However, the company expects 2025 revenue of $58 billion to $61 billion, surpassing analysts’ estimate of $58.52 billion. Despite recent stock declines, Eli Lilly And Co. (NYSE:LLY) is up 16% over the past year.

Despite this, Eli Lilly And Co. (NYSE:LLY) is still on track for 32% annual revenue growth in 2025. With its oncology business growing and treatments for Alzheimer’s and eczema yet to reach full scale, the dip in stock price offers a potentially good investment opportunity. The company is also investing $1.8 billion to expand its manufacturing facilities in Limerick and Kinsale, Ireland. These are efforts to meet the growing demand for incretin therapeutics and produce Kisunla, its newly approved Alzheimer’s treatment.